Mid-Size Japanese Pharmas Turn To U.S. Market For Sales Growth
This article was originally published in PharmAsia News
Executive Summary
Some of Japan's smaller drug makers are following their larger colleagues in seeking new or expanded markets in the United States to offset lagging sales growth at home. Dainippon Sumitomo Pharma is developing its lurasidone now in Phase III trials for the U.S. market, beginning with approval to treat schizophrenia in 2012 and later for depression. Mitsubishi Tanabe Pharma and Shionogi also are looking to the U.S. market for sales. The former plans to apply next year for its drug to treat a kidney failure symptom, while the latter seeks to market an appetite suppressant in 2012. (Click here for more - a subscription may be required